Drugs / Ricinoleic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06033222 | Jan → May 2024 | — | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ricinoleic Acid | “Dietary Supplement: Ricinoleic Acid 750 mg” NCT06033222 ↗ |
| Modality | Small molecule | — CHEMBL1235634 ↗ |
| Route | Oral | “750 mg administered orally” NCT06033222 ↗ |